{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:25:50Z","timestamp":1791822350702,"version":"4.3.4"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T00:00:00Z","timestamp":1719100800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","thegreenjournal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.radonc.2024.110405","type":"journal-article","created":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T19:33:20Z","timestamp":1719257600000},"page":"110405","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["External validation of the lung-molGPA to predict survival in patients treated with stereotactic radiotherapy for brain metastases of non-small cell lung cancer"],"prefix":"10.1016","volume":"198","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2869-4812","authenticated-orcid":false,"given":"Jeroen A.","family":"Crouzen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2178-1646","authenticated-orcid":false,"given":"Mirjam E.","family":"Mast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7117-0459","authenticated-orcid":false,"given":"Martijn","family":"Hakstege","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marike L.D.","family":"Broekman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaouki","family":"Baladi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5019-0354","authenticated-orcid":false,"given":"Bart J.A.","family":"Mertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi D.S.","family":"Nandoe Tewarie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Kerkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maaike J.","family":"Vos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaar W.","family":"Maas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban T.D.","family":"Souwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4534-8468","authenticated-orcid":false,"given":"Ruud G.J.","family":"Wiggenraad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00eblle C.M.G.","family":"van der Voort van Zyp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandy","family":"Kiderlen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4617-0622","authenticated-orcid":false,"given":"Anna L.","family":"Petoukhova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaap D.","family":"Zindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2024.110405_b0005","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/1758834014521110","article-title":"Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies","volume":"6","author":"d'Antonio","year":"2014","journal-title":"Therap Adv Med Oncol"},{"key":"10.1016\/j.radonc.2024.110405_b0010","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1093\/neuonc\/nox077","article-title":"Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study","volume":"19","author":"Cagney","year":"2017","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.radonc.2024.110405_b0015","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.1200\/JCO.20.01255","article-title":"Survival in patients with brain metastases: summary report on the updated diagnosis-specific graded prognostic assessment and definition of the eligibility quotient","volume":"38","author":"Sperduto","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2024.110405_b0020","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ijrobp.2022.03.020","volume":"114","author":"Sperduto","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2024.110405_b0025","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.ijrobp.2007.06.074","article-title":"A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database","volume":"70","author":"Sperduto","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2024.110405_b0030","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2024.110405_b0035","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2024.110405_b0040","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1002\/cncr.23925","article-title":"Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications","volume":"113","author":"Wu","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2024.110405_b0045","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-002560","article-title":"The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data for central Europe from a cohort study","volume":"3","author":"Boch","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.radonc.2024.110405_b0050","article-title":"Clinicopathological and demographical characteristics of non-small cell lung cancer patients with ALK rearrangements: a systematic review and meta-analysis","volume":"9","author":"Fan","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.radonc.2024.110405_b0055","doi-asserted-by":"crossref","first-page":"7268","DOI":"10.1038\/srep07268","article-title":"A large-scale cross-sectional study of ALK rearrangements and EGFR mutations in non-small-cell lung cancer in Chinese Han population","volume":"4","author":"Hong","year":"2014","journal-title":"Sci Rep"},{"key":"10.1016\/j.radonc.2024.110405_b0060","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.7150\/jca.16768","article-title":"Clinicopathological features and relation between anaplastic lymphoma kinase (ALK) mutation and histological subtype of lung adenocarcinoma in Eastern European Caucasian population","volume":"7","author":"Zaric","year":"2016","journal-title":"J Cancer"},{"key":"10.1016\/j.radonc.2024.110405_b0065","doi-asserted-by":"crossref","first-page":"78985","DOI":"10.18632\/oncotarget.12587","article-title":"The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.radonc.2024.110405_b0070","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1186\/s12885-018-4774-y","article-title":"EGFR mutation frequency in Middle East and African non-small cell lung cancer patients: a systematic review and meta-analysis","volume":"18","author":"Benbrahim","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2024.110405_b0075","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1186\/s12885-019-5978-5","article-title":"Molecular features of lung adenocarcinoma in young patients","volume":"19","author":"Chen","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2024.110405_b0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12916-014-0241-z","article-title":"Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): The TRIPOD Statement","volume":"13","author":"Collins","year":"2015","journal-title":"BMC Med"},{"key":"10.1016\/j.radonc.2024.110405_b0085","doi-asserted-by":"crossref","first-page":"450","DOI":"10.12659\/MSM.883213","article-title":"Diagnosis-specific graded prognostic assessment score is valid in patients with brain metastases treated in routine clinical practice in two European countries","volume":"18","author":"Nieder","year":"2012","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.radonc.2024.110405_b0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13014-017-0844-6","article-title":"Validation of the graded prognostic assessment for lung cancer with brain metastases using molecular markers (lung-molGPA)","volume":"12","author":"Nieder","year":"2017","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.radonc.2024.110405_b0095","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.breast.2017.10.006","article-title":"External validation of modified breast graded prognostic assessment for breast cancer patients with brain metastases: a multicentric european experience","volume":"37","author":"Griguolo","year":"2018","journal-title":"Breast"},{"key":"10.1016\/j.radonc.2024.110405_b0100","doi-asserted-by":"crossref","first-page":"178","DOI":"10.14740\/jocmr3248w","article-title":"Validation of the graded prognostic assessment for melanoma using molecular markers (Melanoma-molGPA)","volume":"10","author":"Nieder","year":"2018","journal-title":"J Clin Med Res"},{"key":"10.1016\/j.radonc.2024.110405_b0105","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s11060-018-2958-6","article-title":"Prognostic models for patients with brain metastases after stereotactic radiosurgery with or without whole brain radiotherapy: a validation study","volume":"140","author":"Rice","year":"2018","journal-title":"J Neurooncol"},{"key":"10.1016\/j.radonc.2024.110405_b0110","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2217\/cns-2017-0023","article-title":"Single institution validation of a modified graded prognostic assessment of patients with breast cancer brain metastases","volume":"7","author":"Tai","year":"2018","journal-title":"CNS Oncol"},{"key":"10.1016\/j.radonc.2024.110405_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.cllc.2017.06.011","article-title":"Validation of the disease-specific GPA for patients with 1 to 3 synchronous brain metastases in newly diagnosed NSCLC","volume":"19","author":"Woody","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.radonc.2024.110405_b0120","doi-asserted-by":"crossref","first-page":"8837","DOI":"10.2147\/OTT.S255478","article-title":"Lung-molGPA index predicts survival outcomes of non-small-cell lung cancer patients with synchronous or metachronous brain metastases","volume":"13","author":"Chen","year":"2020","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.radonc.2024.110405_b0125","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000506954","article-title":"External validation of a prognostic score for patients with brain metastases: extended diagnosis-specific graded prognostic assessment","volume":"43","author":"Nieder","year":"2020","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.radonc.2024.110405_b0130","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.01557","article-title":"Validation of nine different prognostic grading indexes for radiosurgery of brain metastases in breast cancer patients and development of an All-encompassing prognostic tool","volume":"10","author":"Weykamp","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.radonc.2024.110405_b0135","doi-asserted-by":"crossref","first-page":"7181","DOI":"10.3390\/curroncol29100565","article-title":"External validation of the graded prognostic assessment in patients with brain metastases from small cell lung cancer","volume":"29","author":"Nieder","year":"2022","journal-title":"Curr Oncol"},{"key":"10.1016\/j.radonc.2024.110405_b0140","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1055\/s-0038-1636442","article-title":"The measurement of performance in probabilistic diagnosis. II. Trustworthiness of the exact values of the diagnostic probabilities","volume":"17","author":"Hilden","year":"1978","journal-title":"Methods Inf Med"},{"key":"10.1016\/j.radonc.2024.110405_b0145","doi-asserted-by":"crossref","unstructured":"Skeie BS, Skeie GO, Enger PO, Ganz JC, Heggdal JI, Ystevik B, et al. Gamma knife surgery in brain melanomas: absence of extracranial metastases and tumor volume strongest indicators of prolonged survival. World Neurosurg. 2011;75(5-6):684-91; discussion 598-603. doi:10.1016\/j.wneu.2010.12.054.","DOI":"10.1016\/j.wneu.2010.12.054"},{"key":"10.1016\/j.radonc.2024.110405_b0150","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3171\/2013.7.JNS13431","article-title":"Tumor volume as a predictor of survival and local control in patients with brain metastases treated with Gamma Knife surgery","volume":"119","author":"Baschnagel","year":"2013","journal-title":"J Neurosurg"},{"key":"10.1016\/j.radonc.2024.110405_b0155","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s11060-022-03981-1","article-title":"A volume matched comparison of survival after radiosurgery in non-small cell lung cancer patients with one versus more than twenty brain metastases","volume":"157","author":"Wei","year":"2022","journal-title":"J Neurooncol"},{"key":"10.1016\/j.radonc.2024.110405_b0160","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.18.00149","article-title":"Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater","volume":"37","author":"Reck","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2024.110405_b0165","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2217\/fon-2021-0795","article-title":"Efficacy of PD-1\/L1 inhibitors in brain metastases of non-small-cell lung cancer: pooled analysis from seven randomized controlled trials","volume":"18","author":"Li","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.radonc.2024.110405_b0170","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1186\/s12885-023-10959-3","article-title":"Clinical benefit of pembrolizumab in treatment of first line non-small cell lung cancer: a systematic review and meta-analysis of clinical characteristics","volume":"23","author":"Liu","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.radonc.2024.110405_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107321","article-title":"Impact of first-line immunotherapy on survival and intracranial outcomes in a cohort of non-small cell lung cancer patients with brain metastases at diagnosis","volume":"184","author":"Nigen","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.radonc.2024.110405_b0180","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1158\/2159-8290.CD-15-0369","article-title":"Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets","volume":"5","author":"Brastianos","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.radonc.2024.110405_b0185","doi-asserted-by":"crossref","first-page":"137","DOI":"10.14791\/btrt.2019.7.e44","article-title":"Discordance of epidermal growth factor receptor mutation between brain metastasis and primary non-small cell lung cancer","volume":"7","author":"Kim","year":"2019","journal-title":"Brain Tumor Res Treat"},{"key":"10.1016\/j.radonc.2024.110405_b0190","first-page":"vdab166","article-title":"Systematic review and meta-analysis of PD-L1 expression discordance between primary tumor and lung cancer brain metastasis","volume":"3","author":"Tonse","year":"2021","journal-title":"Neurooncol Adv"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814024006753?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814024006753?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T19:10:55Z","timestamp":1728328255000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814024006753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":38,"alternative-id":["S0167814024006753"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2024.110405","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"External validation of the lung-molGPA to predict survival in patients treated with stereotactic radiotherapy for brain metastases of non-small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2024.110405","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"110405"}}